Crux Biolabs make Mountain Highway Business Park home
21 July 2020 This week Crux Biolabs is moving to a larger lab premises at the Mountain Highway Business Park in Bayswater. Crux’s growth since obtaining NATA accreditation to ISO 17025 in early 2019 has meant that…
General advice on face masks and coverings for Victoria
Date posted 21 July 2020 For the most up-to-date information, please visit the Department of Health and Human Services Coronavirus Advice webpage. For information targeted to businesses, see “Face masks in the workplace”. If you live within metropolitan…
Face masks in the workplace
Date posted: 21 July 2020 For the most up-to-date information, please visit the Business Victoria Coronavirus webpage. For general advice, see “General advice on face masks and coverings for Victoria”. From 11.59pm on Wednesday 22 July, people living…
UniQuest and CSL Limited partner to develop potential treatment for Sjogren’s Syndrome
20 July 2020 UniQuest, The University of Queensland’s (UQ’s) technology transfer company has announced it will partner with CSL to develop and commercialise UQ’s antigen specific immune tolerance induction (ASITI) technology for the treatment of Sjogren’s Syndrome. Under…
Noxopharm: Independent Data Confirms Idronoxil Achieves Major Industry Goal of Converting ‘COLD’ Tumours to ‘HOT’ Tumours
20 July 2020 Key points: Pre-clinical data indicates that idronoxil (active ingredient in Veyonda®) achieves major goal in converting immunologically ‘COLD’ tumours to ‘HOT’ ‘COLD’ to ‘HOT’ conversion restores cancer-fighting immune cells to tumours, seen as a prerequisite…
MTPConnect and MRFF BioMedTech Horizons Funds 21 Projects In Round 3
20 July 2020 Delivered by MTPConnect, the Australian Government’s $45 million BioMedTech Horizons program is an initiative to support innovative collaborative health technologies, drive discoveries towards proof-of-concept and commercialisation that address key health challenges as well as maximise…
AdAlta Receives US FDA Regulatory Advice Guiding AD-214 Development
20 July 2020 Highlights: Supportive US Food and Drug Administration (FDA) advice received in relation to AdAlta’s lead therapeutic candidate, AD-214 Pre-clinical program and Phase I trial design for AD-214 deemed sufficient to support an Investigational New Drug…
Breakthrough blood test detects positive COVID-19 result in 20 minutes
17 July 2020 World-first research, led by Monash University, has been able to identify positive COVID-19 cases using blood samples in approximately 20 minutes. Researchers developed a simple assay based on commonly used blood typing infrastructure. Positive COVID-19…
PolyNovo receives BARDA funding for Pivotal Trial
14 July 2020 PolyNovo is pleased to announce it has received funding of $15M USD from BARDA to support the Pivotal trial program of NovoSorb BTM. PolyNovo will make a modest co-funding and “in kind” contribution to the…
Scientists describe immune response to COVID-19’s spike protein – the secret to a successful vaccine?
16 July 2020 Scientists have uncovered how a crucial component of the immune system responds to the spike protein of SARS-CoV-2, the virus that causes COVID-19 – important information for future validation of vaccine candidates. Coronavirus particles have…
New training centres to undertake world-leading research
14 July 2020 The Morrison Government is investing in partnerships between universities and industry to produce world-leading research and real-world commercial outcomes while also creating jobs and business opportunities. Minister for Education Dan Tehan today announced five new…
Immutep Announces United States Patent Grant For IMP701 Antibody
16 July 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) announces the grant of patent no. 10,711,060 entitled “Antibody molecules to LAG-3 and uses thereof” by the United States Patent and Trade Mark Office. This…
